飞一般的亮哥
Lv6
2020 积分
2023-08-25 加入
-
Concentration–Response Modeling of ECG Data From Early‐Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk — Experience From the Development Program of Lemborexant
1个月前
已完结
-
P272 NMD670, a novel first-in-class muscle ClC-1 inhibitor, improves symptoms of myasthenia gravis: a randomized, single-dose, double-blind, placebo-controlled study
3个月前
已完结
-
The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis
3个月前
已完结
-
Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis
3个月前
已完结
-
First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)
3个月前
已完结
-
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
4个月前
已完结
-
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
4个月前
已完结
-
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis
4个月前
已完结
-
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension
4个月前
已完结
-
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
4个月前
已完结